Urology News and Research

Latest Urology News and Research

The Journal of Urology publishes results from BioSpecifics XIAFLEX trials on Peyronie's disease

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in Europe and Eurasia, today announced that The Journal of Urology has electronically published the uncorrected proof of the pivotal IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials on its website.

5 Feb 2013

Risk factors identified for renal abnormality in vesicoureteral reflux

Researchers have identified the main risk factors for renal functional abnormalities in children with high-grade vesicoureteral reflux.

4 Feb 2013

Glycemic control low priority in diabetes CVD prevention

Maintaining glycemic control does not reduce the likelihood for cardiovascular disease leading to hospitalization in people with Type 2 diabetes, report US researchers.

4 Feb 2013

Weill Cornell and NewYork-Presbyterian create pioneering Institute for Precision Medicine

Recognizing that medicine is not "one size fits all," Weill Cornell Medical College and NewYork-Presbyterian Hospital have created the pioneering Institute for Precision Medicine at Weill Cornell and NewYork-Presbyterian/Weill Cornell Medical Center. This new, cutting-edge translational medicine research hub will explore the new frontier of precision medicine, offering optimal targeted, individualized treatment based on each patient's genetic profile.

1 Feb 2013

Potty training right from the birth can eliminate need for diapers

Western babies are potty trained later these days and need diapers until an average of three years of age. But even infants can be potty trained. A study by researchers at Sahlgrenska Academy, University of Gothenburg, Sweden, followed 47 infants and their mothers in Vietnam - where potty training starts at birth and the need for diapers is usually eliminated by nine months of age.

31 Jan 2013

Pelvic floor exercises after RP ‘sufficient’

Performing pelvic floor muscle training both before and after radical prostatectomy is no more effective at reducing postoperative urinary incontinence than performing the exercises after surgery, report researchers.

30 Jan 2013

Prediagnostic androgen level not linked to prostate cancer outcome

Low prediagnostic levels of circulating sex hormones are not associated with more aggressive disease in patients with prostate cancer, say US researchers.

28 Jan 2013

Sacral nerve stimulation helps manage children with chronic incontinence

Incontinence is typically a condition associated with adults; however, many children also struggle with incontinence - bladder, bowel or both. In order to help these children, doctors at Nationwide Children's Hospital have turned to a device, typically used in adult patients, to help manage children with chronic incontinence.

24 Jan 2013

Actavis seeks FDA approval to market generic Opana ER

Watson Pharmaceuticals, Inc. today confirmed that Actavis South Atlantic LLC, which was acquired by Watson in October, has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Oxymorphone Hydrochloride Extended-release Tablets.

23 Jan 2013

Dutasteride decreases risk of biopsy detectable prostate cancer by 22.8%

The four-year REDUCE (REduction by DUtasteride of prostate Cancer Events) clinical study evaluated prostate cancer risk reduction in men taking dutasteride, a 5-alpha-reductase inhibitor (5ARI) typically used to treat enlarged prostate.

22 Jan 2013

Golden nanoparticle starves cancer cell to death

How do you annihilate lymphoma without using any drugs? Starve it to death by depriving it of what appears to be a favorite food: HDL cholesterol.

21 Jan 2013

Bladder cancer risk associated with childbearing factors

The risk for bladder cancer in women may decline with increased parity and older age at first birth, researchers report.

21 Jan 2013

FDA approves Allergan’s BOTOX to treat overactive bladder

Allergan, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved BOTOX (onabotulinumtoxinA) for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and frequency in adults who have had an inadequate response to or are intolerant of an anticholinergic medication.

19 Jan 2013